Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Chagpar on Limiting the Spread of COVID-19

March 25th 2020

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer

March 20th 2020

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer

March 19th 2020

Sara A. Hurvitz, MD, discusses available treatment options in early-stage HER2-positive breast cancer.

Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer

March 19th 2020

Oludamilola (Lola) A. Olajide, MD, discusses managing the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in breast cancer.

Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast Cancer

March 13th 2020

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Breast Oncologists Voice Coronavirus Concerns

March 12th 2020

Several faculty who were on site at the 2020 Miami Breast Cancer Conference touch upon COVID-19.

Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer

March 12th 2020

Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.

Burnout in Doctors and Mitigation Strategies

March 10th 2020

What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.

Navigating Treatment Options for Patients With Early-Stage Breast Cancer

March 10th 2020

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

Survivorship Starts at Diagnosis in Breast Cancer

March 10th 2020

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

March 9th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Dr. Tripathy on Personalized Therapy Options in Metastatic Breast Cancer

March 8th 2020

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Exercise Programs Improve Outcomes for Patients With Breast Cancer

March 8th 2020

Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.

Dr. Borgen on the De-Escalation of Surgery in Breast Cancer

March 8th 2020

Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.

Dr. Soto Perez de Celis on Nuances of Treating Older Patients With Breast Cancer

March 8th 2020

Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.

Novel Antibody-Drug Conjugates Show Encouraging Activity in TNBC

March 7th 2020

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.

Rugo Spotlights Potential With Tucatinib, Other Novel Agents in HER2+ Breast Cancer

March 7th 2020

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

All Stakeholders Are Responsible for Genetic Testing

March 7th 2020

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

Immunotherapy Comes of Age in Breast Cancer

March 7th 2020

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

Dr. Hughes on Genetic Testing in Breast Cancer

March 7th 2020

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.